Get the Stockscreener App
2.92
1.74%
0.05
Vistagen Therapeutics Inc stock is traded at $2.92, with a volume of 328.93K.
It is up +1.74% in the last 24 hours and up +45.27% over the past month.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
See More
Previous Close:
$2.87
Open:
$2.84
24h Volume:
328.93K
Relative Volume:
1.28
Market Cap:
$85.14M
Revenue:
$875.70K
Net Income/Loss:
$-39.57M
P/E Ratio:
-2.1754
EPS:
-1.3423
Net Cash Flow:
$-33.65M
1W Performance:
-5.19%
1M Performance:
+45.27%
6M Performance:
+1.04%
1Y Performance:
-13.22%
1-Day Range:
$2.70
$2.9403
1-Week Range:
$2.70
$3.33
52-Week Range:
$1.90
$3.79
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Name
Vistagen Therapeutics Inc
Sector
Industry
Phone
650-577-3600
Address
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
2.92 | 85.70M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-07-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-07-23 | Upgrade | Maxim Group | Hold → Buy |
| Jul-22-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-22-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-20-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Initiated | Jefferies | Buy |
| Jan-04-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Feb-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-28-17 | Initiated | Maxim Group | Buy |
View All
Vistagen Therapeutics Inc Stock (VTGN) Latest News
Using R and stats models for Vistagen Therapeutics Inc. forecastingRSI Divergence and Support Breakout Analysis - Newser
Pattern recognition hints at Vistagen Therapeutics Inc. upsideWeekly Trend Screener with Momentum Picks - Newser
Intraday pattern recognizer results for Vistagen Therapeutics Inc.Trade Plan With Low Risk High Return - Newser
Why Vistagen Therapeutics Inc. stock attracts strong analyst attentionSmart Stock Forecast Using AI Algorithms - Newser
Is Vistagen Therapeutics Inc. stock a good hedge against inflationFree Weekly Stock Watch With Growth Focus - Newser
Predicting Vistagen Therapeutics Inc. trend using moving averagesEquity Signal Recap With Long-Term Summary - Newser
Using Python tools to backtest Vistagen Therapeutics Inc. strategies2-Day Signal Watch with Forecast Outcome - Newser
What are the technical indicators suggesting about Vistagen Therapeutics Inc.Pre Market Trend Scanner From AI Tools - jammulinksnews.com
Vistagen Earnings: Latest Updates on Revolutionary Nose-to-Brain Drug Technology Coming August 7 - Stock Titan
What makes Vistagen Therapeutics Inc. stock price move sharplyFree Pattern Alert With ROI Driven Strategy - Newser
Will Vistagen Therapeutics Inc. see short term momentumFree Swing Trade Entry With Volume Triggers - Newser
Market reaction to Vistagen Therapeutics Inc.’s recent newsPattern Detection for Entry Confirmation Enabled - metal.it
Chart based analysis of Vistagen Therapeutics Inc. trendsSwing Reversal Forecast Based on Patterns - Newser
What makes Vistagen Therapeutics Inc. stock attractive to long term investorsDownside Risk Evaluation and Stock Analysis - Newser
What institutional investors are buying Vistagen Therapeutics Inc. stockOutstanding capital returns - jammulinksnews.com
Should I hold or sell Vistagen Therapeutics Inc. stock in 2025Explosive earnings growth - jammulinksnews.com
Is Vistagen Therapeutics Inc. a growth stock or a value stockOutperformance with explosive growth - jammulinksnews.com
What is the risk reward ratio of investing in Vistagen Therapeutics Inc. stockCapitalize on fast-moving stock opportunities - jammulinksnews.com
When is Vistagen Therapeutics Inc. stock expected to show significant growthDiscover stocks with superior performance - jammulinksnews.com
How volatile is Vistagen Therapeutics Inc. stock compared to the marketBuild wealth steadily with proven methods - jammulinksnews.com
Is it the right time to buy Vistagen Therapeutics Inc. stockGet professional advice for portfolio optimization - jammulinksnews.com
Vistagen Therapeutics Inc. Stock Analysis and ForecastSky-high return potential - PrintWeekIndia
Vistagen Therapeutics Inc Stock (VTGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):